SIREN : 882677420
BIOSSENT is a French company founded 6 years ago, specialized in the sector Fabrication d'autres produits chimiques organiques de base. Based in ANGEAC-CHAMPAGNE (16130), this company of category ETI shows in 2025 a revenue of 3.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3 865 310 € | 4 919 185 € | 4 666 585 € | N/C | N/C |
| Net income | 254 746 € | 722 715 € | 1 058 041 € | 587 273 € | 349 689 € |
| EBITDA | 616 374 € | 1 153 254 € | 1 377 008 € | N/C | N/C |
| Net margin | 6.6% | 14.7% | 22.7% | N/C | N/C |
In 2025, BIOSSENT achieves revenue of 3.9 M€. Revenue is declining over the period 2023-2025 (CAGR: -9.0%). Significant drop of -21% vs 2024. After deducting consumption (666 k€), gross margin stands at 3.2 M€, i.e. a rate of 83%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 616 k€, representing 15.9% of revenue. Warning negative scissor effect: despite revenue change (-21%), EBITDA varies by -47%, reducing margin by 7.5 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 255 k€, i.e. 6.6% of revenue. This profit can be retained or distributed to shareholders.
3 865 310 €
3 199 717 €
616 374 €
290 888 €
254 746 €
15.9%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 86%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 14.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.0%
86.152%
14.839%
0.0
35.8%
In 2025, the debt ratio of BIOSSENT (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2025, the financial autonomy of BIOSSENT (86.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2025, the repayment capacity of BIOSSENT (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 557.68. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.4x. Danger: operating income does not cover interest charges, unsustainable situation.
557.677
0.414
In 2025, the liquidity ratio of BIOSSENT (557.68) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2025, the interest coverage of BIOSSENT (0.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 106 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 55 days. The gap of 51 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Inventory turnover is 171 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 311 days of revenue, i.e. 3.3 M€ to permanently finance.
3 338 816 €
106 j
55 j
171 j
311 j
Based on 74 transactions of similar company sales
(all years),
the value of BIOSSENT is estimated at
347 406 €
(range 153 814€ - 949 847€).
With an EBITDA of 616 374€, the sector multiple of 0.6x is applied.
The price/revenue ratio is 0.11x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 74 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIOSSENT with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication d'autres produits chimiques organiques de base
The revenue of BIOSSENT in 2025 is 3.9 M€.
Yes, BIOSSENT generated a net profit of 255 k€ in 2025.
The headquarters of BIOSSENT is located in ANGEAC-CHAMPAGNE (16130), in the department Charente.
The tax return of BIOSSENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOSSENT operates in the sector Fabrication d'autres produits chimiques organiques de base (NAF code 20.14Z). See the 'Sector positioning' section above to compare the company with its competitors.